This partnership will enhance cancer care access and affordability,
Widen NCD care across Tamil Nadu
Chennai, December 20, 2022: Karkinos Healthcare and Geri Care announced their partnership to bring Non-Communicable Diseases (NCDs) and comprehensive Cancer Care solutions under one roof, to better serve the society at large.
Karkinos Healthcare, is a purpose-driven technology-led oncology platform with an end-to-end patient navigation support, headquartered in Mumbai, India.
Geri Care, is a pioneer Geriatric Care chain, Head quartered in Chennai, India which caters exclusively for senior citizens, providing lifecycle care through its neighbourhood Geriatric Clinics, Assisted Living, Home Visit Programs, and its own multi-specialty hospital.
Speaking on the partnership, Dr. LakshmiPathy Ramesh, Founder & CEO, Geri Care and Dr.V.Srinivasan, Director & Co Founder, Geri Care said, “We are pleased to partner with Karkinos Healthcare as our diagnostics partner in India, for all oncology diagnostic tests that was not conducted in our own facilities thus far. We recognize the necessary skills, capabilities, and expertise that Karkinos Healthcare brings in the onco-care ecosystem, especially in the domain of molecular laboratory and next-gen cancer care solutions.”
Dr. Rejiv Rajendranath, MD DM DNB, Clinical Lead, Geriatric Oncology Services, Geri Care Hospital added “We understand and support the importance of early, preventive cancer screening amongst senior citizens, who are among the vulnerable segment of our society. We expect our partnership with Karkinos Healthcare will enhance the process and access to world-class cancer treatment at affordable cost. We also plan to expand the service to underprivileged senior citizens from our neighborhood. We are hopeful that this step helps in early detection and improve cure ratios of Cancer cases of Tamil Nadu and makes it a state with better wellness quotient.”
“We are glad to announce our alliance with Geri Care, with its senior-citizen centric set up offering the entire range of Geriatric Healthcare services, a first in the country. This is an important partnership that will allow us an opportunity to work with a pool of well-qualified healthcare professionals and oncologists of various disciplines who are experienced in geriatric care treatment and patient care. We seek to provide support and enable community-centric healthcare camps with respect to NCD. The prime focus of Karkinos Healthcare is to create awareness and provide platform for the early detection of cancer in the country. We see this as the first phase of a long and wide-ranging partnership to transform the onco-care ecosystem in the region and beyond,” – says R. Venkataramanan, Founder and Chief Executive Officer, Karkinos Healthcare Pvt. Ltd.
This strategic partnership will lay the groundwork for systematic screening for common cancers in Chennai, with an end-to-end patient navigation support, access to Virtual Tumor Board (VTB) advisory services, opportunity to consult national and international oncology experts of eminence, eventually leading to next-gene sequencing and predictive analytics, which Karkinos Healthcare stands distinguished for.
Karkinos is pioneering the Distributed Cancer Care Network model in India addressing clinical needs of cancer patients, with a focus on early detection of cancer. The company works with multiple healthcare institutions and professionals in the oncology ecosystem, successfully bringing care closer to patients backed by a robust technology platform. Karkinos already offers its services in the states of Kerala, Karnataka, Andhra Pradesh, Telangana, Maharashtra, Madhya Pradesh, West Bengal, Manipur, Delhi NCR and now Tamil Nadu, and is planning to ramp up its operations across India. The company is a member of National Cancer Grid, a group of 260+ cancer focused institutions. Karkinos Healthcare has partnered leading Indian institutions namely IIT Bombay, IIT Guwahati, Cochin University of Science and Technology (CUSAT), and IIT Madras, to promote next generation research in cancer.